Next Article in Journal
Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
Next Article in Special Issue
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Previous Article in Journal
The Hedgehog Inhibitor Cyclopamine Reduces β-Catenin-Tcf Transcriptional Activity, Induces E-Cadherin Expression, and Reduces Invasion in Colorectal Cancer Cells
Previous Article in Special Issue
Ultraviolet Radiation-Induced Cytogenetic Damage in White, Hispanic and Black Skin Melanocytes: A Risk for Cutaneous Melanoma
Article Menu

Export Article

Open AccessReview
Cancers 2015, 7(3), 1900-1924;

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?

Cell and Experimental Pathology, Department of Translational Medicine, Lund University, Clinical Research Centre, Skåne University Hospital, Malmö SE-20502, Sweden
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Academic Editor: Chyi-Chia Richard Lee
Received: 23 June 2015 / Revised: 9 September 2015 / Accepted: 14 September 2015 / Published: 17 September 2015
(This article belongs to the Special Issue Current Topics in Cutaneous Melanoma)
Full-Text   |   PDF [1130 KB, uploaded 17 September 2015]   |  


In recent years, scientists have advocated the use of targeted therapies in the form of drugs that modulate genes and proteins that are directly associated with cancer progression and metastasis. Malignant melanoma is a dreadful cancer type that has been associated with the rapid dissemination of primary tumors to multiple sites, including bone, brain, liver and lungs. The discovery that approximately 40%–50% of malignant melanomas contain a mutation in BRAF at codon 600 gave scientists a new approach to tackle this disease. However, clinical studies on patients have shown that although BRAFi (BRAF inhibitors) trigger early anti-tumor responses, the majority of patients later develop resistance to the therapy. Recent studies have shown that WNT5A plays a key role in enhancing the resistance of melanoma cells to BRAFi. The focus of the current review will be on melanoma development, signaling pathways important to acquired resistance to BRAFi, and why WNT5A inhibitors are attractive candidates to be included in combinatorial therapies for melanoma. View Full-Text
Keywords: melanoma; WNT5A; BRAFi; MAPK/ERK; PI3K-AKT; MITF melanoma; WNT5A; BRAFi; MAPK/ERK; PI3K-AKT; MITF

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Prasad, C.P.; Mohapatra, P.; Andersson, T. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? Cancers 2015, 7, 1900-1924.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top